GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ORIC Pharmaceuticals Inc (STU:4TZ) » Definitions » EV-to-FCF

ORIC Pharmaceuticals (STU:4TZ) EV-to-FCF : -1.99 (As of Mar. 26, 2025)


View and export this data going back to 2020. Start your Free Trial

What is ORIC Pharmaceuticals EV-to-FCF?

EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, ORIC Pharmaceuticals's Enterprise Value is €209.81 Mil. ORIC Pharmaceuticals's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2024 was €-105.41 Mil. Therefore, ORIC Pharmaceuticals's EV-to-FCF for today is -1.99.

The historical rank and industry rank for ORIC Pharmaceuticals's EV-to-FCF or its related term are showing as below:

STU:4TZ' s EV-to-FCF Range Over the Past 10 Years
Min: -11.37   Med: 0   Max: 1.57
Current: -2.38

During the past 7 years, the highest EV-to-FCF of ORIC Pharmaceuticals was 1.57. The lowest was -11.37. And the median was 0.00.

STU:4TZ's EV-to-FCF is ranked worse than
100% of 415 companies
in the Biotechnology industry
Industry Median: 4.49 vs STU:4TZ: -2.38

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.

As of today (2025-03-26), ORIC Pharmaceuticals's stock price is €6.80. ORIC Pharmaceuticals's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2024 was €-1.686. Therefore, ORIC Pharmaceuticals's PE Ratio (TTM) for today is At Loss.


ORIC Pharmaceuticals EV-to-FCF Historical Data

The historical data trend for ORIC Pharmaceuticals's EV-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ORIC Pharmaceuticals EV-to-FCF Chart

ORIC Pharmaceuticals Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
EV-to-FCF
Get a 7-Day Free Trial -20.63 -5.70 -0.80 -3.46 -2.81

ORIC Pharmaceuticals Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
EV-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -3.46 -6.39 -1.94 -4.13 -2.81

Competitive Comparison of ORIC Pharmaceuticals's EV-to-FCF

For the Biotechnology subindustry, ORIC Pharmaceuticals's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


ORIC Pharmaceuticals's EV-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, ORIC Pharmaceuticals's EV-to-FCF distribution charts can be found below:

* The bar in red indicates where ORIC Pharmaceuticals's EV-to-FCF falls into.


';

ORIC Pharmaceuticals EV-to-FCF Calculation

ORIC Pharmaceuticals's EV-to-FCF for today is calculated as:

EV-to-FCF=Enterprise Value (Today)/Free Cash Flow (TTM)
=209.810/-105.411
=-1.99

ORIC Pharmaceuticals's current Enterprise Value is €209.81 Mil.
ORIC Pharmaceuticals's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €-105.41 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


ORIC Pharmaceuticals  (STU:4TZ) EV-to-FCF Explanation

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.

ORIC Pharmaceuticals's PE Ratio (TTM) for today is calculated as:

PE Ratio (TTM)=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=6.80/-1.686
=At Loss

ORIC Pharmaceuticals's share price for today is €6.80.
ORIC Pharmaceuticals's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €-1.686.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.


ORIC Pharmaceuticals EV-to-FCF Related Terms

Thank you for viewing the detailed overview of ORIC Pharmaceuticals's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


ORIC Pharmaceuticals Business Description

Traded in Other Exchanges
Address
240 E. Grand Avenue, 2nd Floor, South San Francisco, CA, USA, 94080
ORIC Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It has a pipeline of therapies designed to counter resistance mechanisms in cancer by leveraging its expertise within three specific areas: hormone-dependent cancers, precision oncology, and key tumor dependencies. The company has product candidates namely ORIC-944, ORIC-114, and ORIC-533. The Company has as one operating segment, focused on the discovery and development of therapies designed to counter the resistance mechanisms in cancer.

ORIC Pharmaceuticals Headlines

No Headlines